| 氯吡格雷抵抗的临床处理 |
| |
| 引用本文： | 王婧. 氯吡格雷抵抗的临床处理[J]. 心血管病学进展, 2012, 33(1): 24-27 |
| |
| 作者姓名： | 王婧 |
| |
| 作者单位： | 北京协和医学院中国医学科学院北京阜外心血管病医院,北京,100037 |
| |
| 摘 要： | 急性冠状动脉综合征的患者尽管接受了标准剂量的氯吡格雷治疗,仍有部分患者发生缺血性心血管事件,称为氯吡格雷抵抗。氯吡格雷抵抗引起的广泛关注使个体化抗血小板药物成为这些患者改善预后的治疗策略。在遗传学检测的辅助下,新型P2Y12受体拮抗剂普拉格雷、替卡格雷和坎格雷拉以及糖蛋白Ⅱb/Ⅲa受体拮抗剂和高剂量氯吡格雷是可能的应对措施。就现有的临床试验研究证据对氯吡格雷抵抗患者的个体化治疗做一综述。
|
| 关 键 词： | 氯吡格雷 氯吡格雷抵抗 普拉格雷 替卡格雷 |
Clinical Strategies for Clopidogrel Resistance |
| |
| WANG Jing. Clinical Strategies for Clopidogrel Resistance[J]. Advances in Cardiovascular Diseases, 2012, 33(1): 24-27 |
| |
| Authors: | WANG Jing |
| |
| Affiliation: | (Department of Cardiology,Cardiovascular Institute & Fuwai Hospital,Peking Union Medical College & Chinese Academy of Medical Science,Beijing 100037,China) |
| |
| Abstract: | Despite providing a standard dose of clopidogrel to patients with acute coronary disease,cardiovascular ischemic events still occurred in some of them thereby indicating a resistance to clopidorel.As clopidogrel resistance increases,healthcare professionals are seeking out tailored antiplatelet therapies to improve clinical outcomes.Novel inhibitors of the P2Y12 receptor such as prasugrel,ticagrelor and cangrelor,as well as glycoprotein Ⅱb/Ⅲa receptor inhibitors and higher doses of clopidogrel with the assistance of genetic testing are probable ways to overcome clopidorel resistance.This article reviews currently available evidence of clinical trials and optimal clinical strategies for individual patients with clopidogrel resistance. |
| |
| Keywords: | clopidogrel clopidogrel resistance prasugrel ticagrelor |
| 本文献已被 CNKI 万方数据 等数据库收录！ |
|
